Jazz Pharmaceuticals PLC (JAZZ)

Debt-to-assets ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	5,107,990	5,110,760	5,686,650	5,689,660	5,693,340	5,695,810	5,990,000	5,992,870	6,018,940	6,247,290	6,489,320	1,853,030	1,848,520	1,843,680	2,069,670	1,576,980	1,573,870	1,570,780	1,567,840	1,565,280
Total assets	US$ in thousands	11,393,400	11,204,100	11,260,500	11,047,100	10,835,300	10,384,700	11,200,100	11,768,900	12,298,600	12,478,200	13,213,000	6,756,470	6,535,900	6,291,960	6,066,500	5,215,300	5,538,900	5,527,850	5,488,660	5,280,240
Debt-to-assets ratio		0.45	0.46	0.51	0.52	0.53	0.55	0.53	0.51	0.49	0.50	0.49	0.27	0.28	0.29	0.34	0.30	0.28	0.28	0.29	0.30

December 31, 2023 calculation

Debt-to-assets ratio = Long-term debt ÷ Total assets
= $5,107,990K ÷ $11,393,400K
= 0.45

The debt-to-assets ratio for Jazz Pharmaceuticals plc has been relatively stable over the past eight quarters, ranging from 0.50 to 0.55. This ratio indicates the proportion of the company's assets financed through debt. With values consistently above 0.50, it suggests that more than half of Jazz Pharmaceuticals' assets are funded through debt, highlighting a moderate level of leverage.

The gradual increase in the debt-to-assets ratio from 0.50 in Q4 2022 to 0.53 in Q4 2023 may indicate a slight increase in debt relative to assets over time. However, the ratio has since stabilized around 0.51-0.52 in the three most recent quarters, suggesting a level of consistency in the company's leverage position.

Overall, a debt-to-assets ratio of around 0.50 to 0.55 indicates that Jazz Pharmaceuticals plc relies moderately on debt financing to support its asset base. It is essential for stakeholders to monitor this ratio over time to assess the company's financial risk and leverage levels.